New research suggests that patients who discontinue new GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass far faster than those who stop conventional lifestyle plans.
Published data in a leading health publication demonstrates that while overweight individuals frequently drop about a fifth of their body weight while using the jabs, the mass returns at an average rate of 0.8 kg per month once they quit.
"People using these treatments must be aware of the danger of fast rebound weight gain when the treatment is stopped," stated expert Dr. Susan Jebb.
Such speed of recovery implies a return to starting weight within about one and a half years.
Weighing Therapies
The analysis, which looked at dozens of studies involving over 9,000 of patients, compared the outcomes of the injectable medications with older methods.
Scientists emphasize that individuals who lose weight through dieting usually have a slower creep back—perhaps 100 grams monthly—after stopping.
Understanding the Quick Regain
Nutrition scientists believe the way of the injections explains the amplified rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 levels several times higher than the body's typical production may cause the body to produce less of its own natural hormone, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement means appetite is uncontrolled, making excessive eating much more probable."
A Chronic Disease?
Health authorities advise the injections for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, given the significant potential of relapse, the therapy should be considered ongoing.
This perspective is echoed by drug manufacturers, who say that the findings "highlight the long-term character of excess weight," similar to managing conditions like high blood pressure.
User Accounts
Users who have stopped the medication describe a intense return of hunger.
"I experienced a trigger activating and you're instantly extremely hungry," said one woman.
This challenge is exacerbated if individuals have not established lasting dietary or behavioural changes during treatment.
Significant Use
Survey data show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is more common among women than men.
- The middle-aged age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, researchers stress that while the jabs are potent tools for weight loss, they are not a magic cure and lasting health benefits hinges on ongoing behavioural management.
